X4 Pharmaceuticals promotes Mary DiBiase to COO effective Sep 8, 2021

X4 Pharmaceuticals, Inc

Dr. DiBiase previously SVP of Technical Operations & Quality; now oversees program/alliance mgmt and IT.
Annual base salary $409,500; eligible for annual cash incentive at 40% of base salary target.
Granted 27,000 RSUs vesting equally over three years.
Severance terms include 12-month base salary continuation and accelerated equity vesting on qualifying termination.
Promotion supports late-stage development of mavorixafor and preparations for potential commercialization.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Mary DiBiase

Chief Operating Officer

XFOR · X4 Pharmaceuticals, Inc

Effective: 2021-09-08
Filed: September 10, 2021, 7:59 PM ET

On September 8, 2021, X4 Pharmaceuticals, Inc. (the “Company”) announced the appointment of Mary DiBiase, Ph.D., age 60, as the Company’s Chief Operating Officer, effective as of September 8, 2021 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mary DiBiase was appointed as Chief Operating Officer at X4 Pharmaceuticals, Inc.

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On September 8, 2021, X4 Pharmaceuticals, Inc. (the “Company”) announced the appointment of Mary DiBiase, Ph.D., age 60, as the Company’s Chief Operating Officer, effective as of September 8, 2021 (the “Effective Date”).

View on SEC.gov

X4 Pharmaceuticals, Inc filing history →

Source: SEC EDGAR

accession 0001628280-21-018381

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.